ELAVL1 and diabetic kidney disease: These in vitro and in vivo results indicate that under pathological conditions of DKD, GSK-3β expression and activity are up-regulated to induce HuR but inhibit TTP expression in podocytes, which leads to podocyte injury and inflammation thereby promoting the progression of DKD (Fig. 8).